Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;8(4):309-314.
doi: 10.5114/ceh.2022.122275. Epub 2022 Dec 28.

Autoantibodies: are they a clue for liver diseases?

Salma Abdel Megeed Nagi  1 , Bassam Abdel Hakam Ayoub  1 , Mohammed Abdel-Hafez Ali  1 , Sally Waheed Elkhadry  2 , Heba Mohamed Abdallah  3 , Marwa Sabry Rizk  1
Affiliations

Autoantibodies: are they a clue for liver diseases?

Salma Abdel Megeed Nagi et al. Clin Exp Hepatol. 2022 Dec.

Abstract

Introduction: Autoantibody testing has contributed to both biological and clinical insights in managing patients with liver disease. These autoantibodies often have clinical value for the diagnosis, disease activity and/or prognosis.

Aim of the study: We aimed to investigate the potential application of auto-antibodies in different etiologies of non-autoimmune liver diseases.

Material and methods: This study was conducted on 53 infants and children with chronic liver diseases. The patients were subjected to clinical history and examination, laboratory investigations and abdominal ultrasound. Serum of all infants and children was tested for measurement of antiprothrombin antibody and anti-b2-glycoprotein I (ab2GPI) and anticardiolipin (ACL) auto-antibodies using a fully-automated enzyme linked immunosorbent assay (ELISA) system.

Results: The mean age of the infants with cholestatic liver diseases was significantly lower than those with metabolic liver diseases, hepatitis C virus (HCV) and vascular liver diseases (p < 0.05). The gender distribution was proportionate in all groups (p = 0.703). Autoantibodies showed significant variations among different etiologies of chronic liver diseases. he incidence of ab2GPI and ACL was significantly increased in both HCV (94.7% and 78.9%, respectively) and vascular liver diseases patients (90.9% and 72.7%, respectively) (p < 0.05). Antiprothrombin antibodies were found in 81.8% of vascular liver disease patients. Interestingly, all types of autoantibodies were deficient in cholestatic and metabolic liver diseases.

Conclusions: Testing for liver-related autoantibodies should be included in the workup of patients with chronic liver diseases. Further studies are needed to explain the cause-effect association of ACL, ab2GPI and antiprothrombin with chronic HCV and vascular liver diseases.

Keywords: anti-b2-glycoprotein antibodies; anticardiolipin antibodies; antiprothrombin antibodies; non-autoimmune liver diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in autoimmune liver disease–clinical and diagnostic relevance. Front Immunol 2018; 9: 609. - PMC - PubMed
    1. Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol 2010; 24: 225-231. - PMC - PubMed
    1. Himoto T, Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights 2013; 4: 39-53. - PMC - PubMed
    1. Ghonaim M, Al-Ghamdi A, El-Bana H, et al. Autoantibodies in chronic liver disease. Egypt J Immunol 2005; 12: 101-111. - PubMed
    1. Seessle J, Gotthardt DN, Schäfer M, et al. Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy. J Inherit Metab Dis 2016; 39: 125-130. - PubMed